Ustekinumab 45mg Injection

Ustekinumab 45mg Injection is a prescription biologic medicine containing ustekinumab, a human monoclonal antibody that selectively targets interleukin-12 (IL-12) and interleukin-23 (IL-23). It is used for the treatment of certain immune-mediated inflammatory conditions, including moderate-to-severe plaque psoriasis and active psoriatic arthritis, according to the applicable indication and prescribing guidelines.

Ustekinumab is the active ingredient in Stelara®, the reference biologic. Ustekinumab 45mg products may be marketed under different brand names depending on the manufacturer and country.

Product Information

Generic Name

Ustekinumab 45mg

Reference Brand

Stelara®

Drug Class

Biologic / IL-12 and IL-23 Inhibitor

Indications

Plaque Psoriasis / Psoriatic Arthritis

Form

Injection

Strength

45mg

Route

Subcutaneous Injection

Prescription

Yes

Active Ingredient

Ustekinumab

Packing

Manufacturer Dependent

Generic Stelara® / Ustekinumab 45mg

Stelara® is the reference brand containing ustekinumab. Ustekinumab 45mg products may be available as biosimilars or other approved alternatives depending on the country and regulatory authorization.

For SEO purposes, the strongest primary product name is:

Ustekinumab 45mg Injection

Secondary terms such as Generic Stelara®, Stelara 45mg, Ustekinumab biosimilar, and Ustekinumab injection can be used as supporting keywords where factually appropriate.

Availability & Ordering

Patients searching for Ustekinumab 45mg Injection, Buy Ustekinumab 45mg Online, Generic Stelara®, Ustekinumab 45mg Price, Ustekinumab for Psoriasis, Ustekinumab for Psoriatic Arthritis, Ustekinumab Biologic Injection, and Ustekinumab IL-12/23 Inhibitor can find prescription products through licensed pharmaceutical suppliers, subject to local prescription and regulatory requirements.

How it works

Ustekinumab is a human monoclonal antibody that binds to the p40 protein subunit shared by IL-12 and IL-23. By inhibiting these cytokine pathways, it reduces inflammatory immune activity associated with psoriasis and psoriatic arthritis.

Ustekinumab 45mg may be prescribed for eligible patients with:

• Moderate-to-severe plaque psoriasis
• Active psoriatic arthritis

The appropriate dose and treatment interval depend on the patient's condition, body weight, age, and the prescribing information applicable to the specific product.